3-pyridineboronie acid MIDA ester | 1311484-51-1

• 英文名称: 3-pyridineboronie acid MIDA ester
• CAS: 1311484-51-1
• 化学式: C₁₀H₁₁BN₂O₄
• 分子量: 234.019
• InChiKey: ZZUOIDPMHJJHND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为反应物：
  描述：

  2-氯噻吩 、 3-pyridineboronie acid MIDA ester 在 potassium phosphate 、 C₂₆H₃₃ClFeNPd 、 四丁基溴化铵 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 水 为溶剂， 反应 24.0h， 以85%的产率得到3-(2-噻吩基)吡啶
  参考文献：
  名称：

  Palladacycle-catalyzed Suzuki–Miyaura reaction of aryl/heteroaryl halides with MIDA boronates in EtOH/H₂O or H₂O

  摘要：

  通过良好到优秀的产率，一系列的单取代或双取代芳基化合物通过钯环催化的Suzuki-Miyaura反应合成，使用各种N-甲基亚胺二乙酸酯硼酸酯与芳基/杂环芳基卤代烃在乙醇/水或水中反应。

  DOI：

  10.1039/c4ra07486f

文献信息

• [EN] 2,3,5 TRISUBSTITUTED ARYL AND HETEROARYL AMINO DERIVATIVES, COMPOSITIONS, AND METHODS OF USE<br/>[FR] DÉRIVÉS AMINÉS D'HÉTÉROARYLE ET D'ARYLE 2,3,5 TRISUBSTITUÉS, COMPOSITIONS ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：NEUROTHERAPEUTICS PHARMA INC

  公开号：WO2013059648A1

  公开（公告）日：2013-04-25

  Compounds are disclosed that have a formula represented by the following:(I) wherein Cy, L1 R1, R2a, R2b, R3, R4, n, and L2 are as described herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, inflammatory pain, insomnia, ischemia, migraine, migraine with aura, migraine without aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, itch, excessive itch, Pruritis, neuropathic pruritis, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

  已披露具有以下表示的化合物的公式：(I)，其中Cy、L1、R1、R2a、R2b、R3、R4、n和L2如本文所述。这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如成瘾障碍、阿尔茨海默病、焦虑障碍、腹水、自闭症、躁郁症、癌症、抑郁症、内皮角膜营养不良、水肿、癫痫、青光眼、亨廷顿病、炎症性疼痛、失眠、缺血、偏头痛、伴有先兆的偏头痛、无先兆的偏头痛、神经病性疼痛、伤害性神经痛、伤害性疼痛、眼部疾病、疼痛、瘙痒、过度瘙痒、瘙痒、神经性瘙痒、帕金森病、人格障碍、带状疱疹后神经痛、精神病、精神分裂症、癫痫障碍、耳鸣和戒断综合症等。
• The Multiple Facets of Iodine(III) Compounds in an Unprecedented Catalytic Auto-amination for Chiral Amine Synthesis
  作者：Julien Buendia、Gwendal Grelier、Benjamin Darses、Amanda G. Jarvis、Frédéric Taran、Philippe Dauban

  DOI：10.1002/anie.201602022

  日期：2016.6.20

  Iodine(III) reagents are used in catalytic one‐pot reactions, first as both oxidants and substrates, then as cross‐coupling partners, to afford chiral polyfunctionalized amines. The strategy relies on an initial catalytic auto C(sp3)−H amination of the iodine(III) oxidant, which delivers an amine‐derived iodine(I) product that is subsequently used in palladium‐catalyzed cross‐couplings to afford a

  碘（III）试剂用于催化一锅法反应，首先用作氧化剂和底物，然后用作交叉偶联伙伴，以提供手性多官能胺。该策略依赖于碘（III）氧化剂的初始催化自动C（sp 3）-H胺化反应，该胺可提供胺衍生的碘（I）产品，该产品随后用于钯催化的交叉偶联中，从而提供多种具有高产量和出色的立体选择性的有用构建基块。这项研究证明了高价碘试剂的自我胺化的概念，这增加了芳基部分的价值。
• Structure–Activity Relationship (SAR) Study of Ethyl 2-Amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4<i>H</i>-chromene-3-carboxylate (CXL017) and the Potential of the Lead against Multidrug Resistance in Cancer Treatment
  作者：Gopalakrishnan Aridoss、Bo Zhou、David L. Hermanson、Nicholas P. Bleeker、Chengguo Xing

  DOI：10.1021/jm300515q

  日期：2012.6.14

  Multidrug resistance (MDR) against standard therapies poses a serious challenge in cancer treatment, and there is a clinical need for new anticancer agents that would selectively target MDR malignancies. Our previous studies have identified a 4H-chromene system, CXL017 (4) as an example, that can preferentially kill MDR cancer cells. To further improve its potency, we have performed detailed structure-activity relationship (SAR) studies at the 3, 4, and 6 positions of the 4H-chromene system. The results reveal that the 3 and 4 positions prefer rigid and hydrophobic functional groups while the 6 position prefers a meta or para-substituted aryl functional group and the substituent should be small and hydrophilic. We have also identified and characterized nine MDR cancer cells that acquire MDR through different mechanisms and demonstrated the scope of our new lead, 9g, to selectively target different MDR cancers, which holds promise to help manage MDR in cancer treatment.
• Heteroarylboronates in Rhodium-Catalyzed 1,4-Addition to Enones
  作者：Fabian Albrecht、Oliver Sowada、Meryem Fistikci、Mike M. K. Boysen

  DOI：10.1021/ol502630w

  日期：2014.10.3

  Rhodium(I)-catalyzed 1,4-addition of aryl and alkenylboronic acids to alpha,beta-unsaturated carbonyl compounds is well established, but the transfer of heteroaryl residues in this reaction remains underdeveloped. We have studied heteroaryl MIDA and pinacol boronates as alternatives to the labile boronic acid counterparts. Under racemic conditions, 12 adducts with heteroaryl residues, among them unsubstituted 3- and 4-pyridinyl, 2-furanyl, thienyl, and pyrrolyl groups, were obtained in moderate to excellent yields. The enantioselective version of the reaction proved highly sensitive to the electronic character of the heteroaryl substituents, with boronates carrying electron-rich residues giving modest to high yields but consistently high enantiomeric excesses.